Home > Boards > US Listed > Biotechs > Aurinia Pharmaceuticals Inc (AUPH)

KZR still at it, LE & LN

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
lidopete Member Profile
 
Followed By 0
Posts 552
Boards Moderated 0
Alias Born 07/16/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/22/2021 4:31:38 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/17/2021 4:04:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2021 5:02:32 PM
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire - 9/15/2021 1:11:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 6:17:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:12:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:11:39 PM
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/10/2021 1:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2021 4:05:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2021 4:04:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/27/2021 4:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2021 4:16:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2021 4:07:54 PM
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases Business Wire - 8/17/2021 6:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/10/2021 4:09:58 PM
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference Business Wire - 8/9/2021 7:55:00 AM
SCWorx, Aurinia Pharmaceuticals leads healthcare gainers; Dicerna Pharmaceuticals, iCAD among major losers Seeking Alpha - 8/6/2021 11:02:32 AM
Aurinia Pharma extends gains following robust Q2 top-line growth Seeking Alpha - 8/6/2021 6:08:45 AM
Aurinia Pharma EPS misses by $0.01, beats on revenue Seeking Alpha - 8/5/2021 4:16:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 4:14:46 PM
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights Business Wire - 8/5/2021 4:05:00 PM
Eyes will be on Aurinia's lupus drug Lupkynis during Q2 2021 earnings today Seeking Alpha - 8/5/2021 11:46:57 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/29/2021 4:11:23 PM
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021 Business Wire - 7/26/2021 6:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/19/2021 6:02:19 AM
lidopete   Thursday, 09/17/20 05:47:23 PM
Re: None
Post # of 13638 
KZR still at it, LE & LN

KZR Alert in News Feed
TheFly.com

TODAY, SEPTEMBER 17, 2020
KZR
16:02
Hot Stocks
Kezar Life highlights data from MISSION study during PANLAR 2020
Kezar Life Sciences highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals of KZR-616 in patients with systemic lupus erythematosus and lupus nephritis at the Pan-American Congress of Rheumatology. The data were presented in a poster titled "Treatment of Systemic Lupus Erythematosus with the Immunoproteasome Inhibitor KZR-616: Results from the First 5 Cohorts of the MISSION Study, an Open-label Phase 1b Dose-Escalation Study" by study investigator Richard Furie, M.D., Chief, Division of Rheumatology, Northwell Health in New York. The poster can be found on Kezar's corporate website under the "Science" section. "Lupus and lupus nephritis are life-threatening diseases that disproportionately impact young Latina women in the prime of their life, and there is an urgent need for new treatment options that can target the full spectrum of their disease and don't cause debilitating side effects that add to the disease burden," said Dr. Furie. "These encouraging early positive data suggest that the novel mechanism of KZR-616 has the potential to address the underlying drivers of inflammation, resulting in improvements across organ systems in this disease." MISSION is a Phase 1b/2 study of KZR-616 in SLE patients with and without nephritis. The Phase 1b portion has completed enrollment in the final cohort, which is evaluating a 75 mg dose of KZR-616. The Phase 2 portion exclusively in LN is actively enrolling.

Related articles
FRIDAY, SEPTEMBER

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences